Lyell Immunopharma Inc (NASDAQ:LYEL) has a beta value of -0.56 and has seen 1.4 million shares traded in the last trading session. The company, currently valued at $640.33M, closed the last trade at $2.52 per share which meant it gained $0.33 on the day or 15.07% during that session. The LYEL stock price is -57.54% off its 52-week high price of $3.97 and 47.62% above the 52-week low of $1.32. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.71 million shares traded. The 3-month trading volume is 924.46K shares.
Lyell Immunopharma Inc (NASDAQ:LYEL) trade information
Sporting 15.07% in the green in last session, the stock has traded in the green over the last five days, when the LYEL stock price touched $2.52 or saw a rise of 4.18%. Year-to-date, Lyell Immunopharma Inc shares have moved 29.90%, while the 5-day performance has seen it change 21.15%. Over the past 30 days, the shares of Lyell Immunopharma Inc (NASDAQ:LYEL) have changed 0.40%. Short interest in the company has seen 18.1 million shares shorted with days to cover at 20.43.
Lyell Immunopharma Inc (LYEL) estimates and forecasts
Figures show that Lyell Immunopharma Inc shares have underperformed across the wider relevant industry. The company’s shares have gained 76.22% over the past 6 months, with this year growth rate of 2.15%, compared to 9.00% for the industry. Other than that, the company has, however, increased its growth outlook for the 2024 fiscal year revenue. Growth estimates for the current quarter are 22.20% and 19.20% for the next quarter.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -15.28% over the past 5 years. Earnings growth for 2024 is a modest 8.52% while over the next 5 years, the company’s earnings are expected to decrease by -7.90%.
LYEL Dividends
Lyell Immunopharma Inc is expected to release its next earnings report in May this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Lyell Immunopharma Inc (NASDAQ:LYEL)’s Major holders
Insiders own 15.59% of the company shares, while shares held by institutions stand at 72.88% with a share float percentage of 86.34%. Investors are also buoyed by the number of investors in a company, with Lyell Immunopharma Inc having a total of 167 institutions that hold shares in the company. The top two institutional holders are MWG Management Ltd with over 20.16 million shares worth more than $64.12 million. As of Jun 29, 2023, MWG Management Ltd held 8.03% of shares outstanding.
The other major institutional holder is Vanguard Group Inc, with the holding of over 16.88 million shares as of Jun 29, 2023. The firm’s total holdings are worth over $53.67 million and represent 6.72% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Price (T.Rowe) Health Sciences Fund. As of Jun 29, 2023, the former fund manager holds about 2.46% shares in the company for having 6.17 million shares of worth $19.63 million while later fund manager owns 4.96 million shares of worth $15.77 million as of Jun 29, 2023, which makes it owner of about 1.98% of company’s outstanding stock.
